We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TSVT Up on Acquisition Agreement With BMY for $286 Million
Read MoreHide Full Article
Shares of 2seventy bio, Inc. (TSVT - Free Report) gained 5.26% after the company announced a definitive merger agreement with Bristol Myers Squibb (BMY - Free Report) .
Per the terms of the deal, BMY will acquire all of the outstanding shares of 2seventy bio for $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or $102 million net of estimated cash. The deal represents an 88% premium to TSVT’s closing price of $2.66 on March 7, 2025.
Investors cheered the premium offered and shares gained another 3.56% in after-hours trading.
In the past year, shares of TVST plunged 40.8% compared with the industry’s 7.2% decline.
Image Source: Zacks Investment Research
More on TSVT’s Deal With BMY
2seventy bio’s board of directors has unanimously recommended that stockholders tender their shares in the offer commenced by BMY.
The acquisition is expected to be closed in the second quarter of 2025.
Meanwhile, certain stockholders of TSVT who own approximately 5.3% of the outstanding shares have entered into tender and support agreements, following which they have agreed to tender all of their owned shares in the offer.
Rationale Behind the TSVT, BMY Deal
TSVT came into existence after bluebird bio spun off its oncology portfolio and programs from its severe genetic disease portfolio and programs into a separate, publicly traded company.
However, TSVT has been facing challenges for quite some time now and is looking to maximize shareholder value.
We note that BMY and TSVT have an agreement in place, whereby both companies equally share profits and losses related to development, manufacturing, and commercialization of Abecma in the United States.
BMY is responsible for the manufacturing and commercialization of Abecma outside the United States.
Abecma is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 monoclonal antibody.
In April 2024, the FDA approved Abecma for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy.
However, in September 2024, TSVT and BMY announced the discontinuation of enrollment in their ongoing phase III KarMMa-9 study evaluating Abecma with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma who have suboptimal response to autologous stem cell transplant.
Earlier, TSVT had entered into an asset purchase agreement with Regeneron (REGN - Free Report) to focus on the development and commercialization of Abecma.
TSVT sold all of the assets related to its solid tumor and other oncology and autoimmune cell therapy programs, including the bbT369 program in B-NHL, SC-DARIC33 in AML, MUC16 in ovarian cancer, MAGE-A4, autoimmune, and several unnamed targets to REGN.
This transaction closed in April 2024 and REGN assumed all of the ongoing program infrastructure and personnel costs related to these programs.
As a part of its strategic alignment, TSVT had earlier entered into an asset purchase agreement with Novo Nordisk (NVO - Free Report) as well.
Per the terms of this agreement, NVO acquired TSVT’s program for the research, development, manufacture, regulatory approval, and commercialization of gene therapy products exploiting the megaTAL Platform, which is directed to the treatment, diagnosis and prevention of hemophilia.
Image: Bigstock
TSVT Up on Acquisition Agreement With BMY for $286 Million
Shares of 2seventy bio, Inc. (TSVT - Free Report) gained 5.26% after the company announced a definitive merger agreement with Bristol Myers Squibb (BMY - Free Report) .
Per the terms of the deal, BMY will acquire all of the outstanding shares of 2seventy bio for $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or $102 million net of estimated cash. The deal represents an 88% premium to TSVT’s closing price of $2.66 on March 7, 2025.
Investors cheered the premium offered and shares gained another 3.56% in after-hours trading.
In the past year, shares of TVST plunged 40.8% compared with the industry’s 7.2% decline.
Image Source: Zacks Investment Research
More on TSVT’s Deal With BMY
2seventy bio’s board of directors has unanimously recommended that stockholders tender their shares in the offer commenced by BMY.
The acquisition is expected to be closed in the second quarter of 2025.
Meanwhile, certain stockholders of TSVT who own approximately 5.3% of the outstanding shares have entered into tender and support agreements, following which they have agreed to tender all of their owned shares in the offer.
Rationale Behind the TSVT, BMY Deal
TSVT came into existence after bluebird bio spun off its oncology portfolio and programs from its severe genetic disease portfolio and programs into a separate, publicly traded company.
However, TSVT has been facing challenges for quite some time now and is looking to maximize shareholder value.
We note that BMY and TSVT have an agreement in place, whereby both companies equally share profits and losses related to development, manufacturing, and commercialization of Abecma in the United States.
BMY is responsible for the manufacturing and commercialization of Abecma outside the United States.
Abecma is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 monoclonal antibody.
In April 2024, the FDA approved Abecma for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy.
However, in September 2024, TSVT and BMY announced the discontinuation of enrollment in their ongoing phase III KarMMa-9 study evaluating Abecma with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma who have suboptimal response to autologous stem cell transplant.
Earlier, TSVT had entered into an asset purchase agreement with Regeneron (REGN - Free Report) to focus on the development and commercialization of Abecma.
TSVT sold all of the assets related to its solid tumor and other oncology and autoimmune cell therapy programs, including the bbT369 program in B-NHL, SC-DARIC33 in AML, MUC16 in ovarian cancer, MAGE-A4, autoimmune, and several unnamed targets to REGN.
This transaction closed in April 2024 and REGN assumed all of the ongoing program infrastructure and personnel costs related to these programs.
As a part of its strategic alignment, TSVT had earlier entered into an asset purchase agreement with Novo Nordisk (NVO - Free Report) as well.
Per the terms of this agreement, NVO acquired TSVT’s program for the research, development, manufacture, regulatory approval, and commercialization of gene therapy products exploiting the megaTAL Platform, which is directed to the treatment, diagnosis and prevention of hemophilia.
TSVT’s Zacks Rank
TSVT currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.